Heart Disease Research
Research into the impact of a particular protein on an individual's risk of developing cardiovascular disease had to be cut short as its findings were so important, according to the scientists who conducted it.
Health experts from McGill University Health Centre were among those who worked on the project, with the institution explaining why the study was brought to an early end.
Their intentions were to provide health care advice to patients with high levels in their body of high-sensitivity C-reactive protein.
Almost 18,000 participants were included in the test population, across which medical experts assessed the impact of therapies on people with high levels of the protein.
But the early stages of their research found that treating such individuals with statins can reduce the risk of cardiovascular disease by almost half.
In light of the 44 per cent benefit for patients treated with statins, the scientists called a halt to their study in order to present their findings as soon as possible.
Recent health care advice was given to diabetes patients in light of an analysis of previously published research on the impact of treatments for the condition on cardiovascular risk.
Scientists from Johns Hopkins Bloomberg School of Public Health noted that some concern surrounds the diabetes drug rosiglitazone, whereas previous treatment metformin has been linked with protecting against the risk of heart disease.
